Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (5y) (2018 - 2026)
Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (5y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
| 10 |
Theravance Biopharma |
839.69 Mn |
445.03 Mn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
-22.24% |
| Dec 31, 2025 |
4.79% |
| Sep 30, 2025 |
15.43% |
| Jun 30, 2025 |
23.49% |
| Mar 31, 2025 |
30.39% |
| Dec 31, 2024 |
18.72% |
| Sep 30, 2024 |
26.31% |
| Jun 30, 2024 |
16.13% |
| Mar 31, 2024 |
30.62% |
| Dec 31, 2023 |
29.92% |
| Sep 30, 2023 |
31.52% |
| Jun 30, 2023 |
17.45% |
| Mar 31, 2023 |
19.44% |
| Dec 31, 2022 |
15.38% |
| Sep 30, 2022 |
73.81% |
| Jun 30, 2022 |
17.89% |
| Mar 31, 2022 |
17.49% |
| Dec 31, 2021 |
18.97% |
| Sep 30, 2021 |
21.12% |
| Jun 30, 2021 |
17.75% |
